Pembrolizumab With or Without Chemotherapy in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: Updated Results of the Phase III KEYNOTE-048 Study
暂无分享,去创建一个
R. Greil | I. Braña | A. Psyrri | D. Rischin | R. Swaby | B. Burtness | N. Ngamphaiboon | B. Hughes | R. Mesía | A. Bratland | D. Soulières | G. de Castro | T. Fuereder | M. Tahara | P. Neupane | T. Rordorf | W. Z. Wan Ishak | N. Basté | B. Gumuscu | Jianxin Lin | K. Harrington
[1] I. Marschner,et al. The validity of progression‐free survival 2 as a surrogate trial end point for overall survival , 2022, Cancer.
[2] C. R. Leemans,et al. Head and neck squamous cell carcinoma , 2020, Nature Reviews Disease Primers.
[3] V. Grégoire,et al. Squamous cell carcinoma of the oral cavity, larynx, oropharynx and hypopharynx: EHNS-ESMO-ESTRO Clinical Practice Guidelines for diagnosis, treatment and follow-up. , 2020, Annals of oncology : official journal of the European Society for Medical Oncology.
[4] Y. Nishimura,et al. Safety and efficacy of cetuximab-containing chemotherapy after immune checkpoint inhibitors for patients with squamous cell carcinoma of the head and neck: a single-center retrospective study , 2020, Anti-cancer drugs.
[5] K. Harrington,et al. Further clinical interpretation and implications of KEYNOTE-048 findings – Authors' reply , 2020, The Lancet.
[6] R. Tishler,et al. Chemotherapy after immune checkpoint blockade in patients with recurrent, metastatic squamous cell carcinoma of the head and neck. , 2020, Oral oncology.
[7] Jason M. Johnson,et al. Response rates and survival to systemic therapy after immune checkpoint inhibitor failure in recurrent/metastatic head and neck squamous cell carcinoma. , 2019, Oral oncology.
[8] Hung-Ming Wang,et al. Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study , 2019, The Lancet.
[9] F. Bidault,et al. Response to salvage chemotherapy after progression on immune checkpoint inhibitors in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck. , 2019, European journal of cancer.
[10] K. Harrington,et al. Nivolumab treatment beyond RECIST‐defined progression in recurrent or metastatic squamous cell carcinoma of the head and neck in CheckMate 141: A subgroup analysis of a randomized phase 3 clinical trial , 2019, Cancer.
[11] O. V. Matorin,et al. Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study , 2019, The Lancet.
[12] J. Machiels,et al. Pembrolizumab for recurrent head and neck squamous cell carcinoma (HNSCC): Post hoc analyses of treatment options from the phase III KEYNOTE-040 trial. , 2018, Annals of oncology : official journal of the European Society for Medical Oncology.
[13] Jeremy M G Taylor,et al. Cigarette use, comorbidities, and prognosis in a prospective head and neck squamous cell carcinoma population , 2016, Head & neck.
[14] J. Radford. Nivolumab for recurrent squamous-cell carcinoma of the head and neck , 2016, BDJ.
[15] K. Ang,et al. Human papillomavirus and survival of patients with oropharyngeal cancer. , 2010, The New England journal of medicine.
[16] S. Taylor. Head and neck cancer. , 1991, Cancer chemotherapy and biological response modifiers.